Heritage Pharmaceuticals Inc — FDA Facility Profile

FEI 3013995812

Heritage Pharmaceuticals Inc is an FDA-inspected facility (FEI 3013995812) located in East Brunswick, NJ, US. RegDataLab tracks 3 FDA inspections and 1 compliance action at this facility.

Reviewing Heritage Pharmaceuticals Inc as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Heritage Pharmaceuticals Inc yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

What FDA found at this site

Latest inspection
Dec 14, 2017: No Action Indicated (NAI)
Inspections on record
3 (1 OAI, 2 NAI)
Last OAI inspection
May 27, 2015
Warning letters
1 listed by FDA for this FEI, latest Nov 5, 2015
Recalls as the recalling firm
6, latest Jul 30, 2026

A Form 483 lists an inspector's observations. OAI means FDA recommends regulatory and/or administrative action. A warning letter is FDA's formal enforcement notice. No record here does not establish that a site is safe. Check this site on FDA's Data Dashboard.

Inspections and what FDA cited

Newest first. Citations are the inspector observations FDA publishes for the inspection.

DateResultWhat FDA cited
Dec 14, 2017No Action Indicated (NAI)No citations listed
Oct 3, 2016No Action Indicated (NAI)No citations listed
May 27, 2015Official Action Indicated (OAI)Late submission of 15-day report (21 CFR 314.80(c)(1)(i))
Failure to report non-alert ADEs (21 CFR 314.80(c)(2))
Interval (21 CFR 314.80(c)(2))
Late submission of quarterly safety reports (21 CFR 314.80(c)(2))
and 3 more

Recalls

Newest first. Recalls FDA's Enforcement Report lists with this FEI as the recalling firm. The recalling firm is not always the site that made the product. Search FDA's Enforcement Report by recall number.

DateClassRecallProduct and reason
Jul 30, 2026Not yet classifiedD-0768-2026CLINDAMYCIN PALMITATE HYDROCHLORIDE FOR ORAL SOLUTION, USP, 75 mg/5 mL, Rx Only, 100 mL…
Presence of Foreign Substance: presence of particles and white flakes in the reconstituted bottles.
Oct 6, 2025Not yet classifiedD-0107-2026Desipramine Hydrochloride Tablets, USP, 10 mg, 100 - count bottle (NDC 23155-578-01), Rx… and 5 more products
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Nov 23, 2022Not yet classifiedD-0072-2023Desmopressin Acetate Tablets 0.2mg, 100-count bottles, RX Only, Distributed by: Avet…
Subpotent Drug
Apr 21, 2021Not yet classifiedD-0367-2021Acyclovir Tablets, USP, 400 mg, 100 Tablets, Rx Only, Distributed by: Avet Pharmaceuticals…
Labeling: Incorrect or Missing Lot and/or Exp Date
Oct 23, 2020Not yet classifiedD-0108-2021Felodipine Extended Release Tablets, USP 10 mg,100-count bottle, Rx only, Distributed by…
Failed impurities/ degradation specifications: Out of specification impurity results were observed during routine testing of stability…
May 3, 2019Not yet classifiedD-1287-2019Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only Manufactured by… and 4 more products
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim…

Facility details

Company
Heritage Pharmaceuticals Inc
Location
East Brunswick, NJ (US)
Source
inspections

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.